Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Status:
Completed
Trial end date:
2018-03-16
Target enrollment:
Participant gender:
Summary
Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with
ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to
one or more nonsteroidal anti-inflammatory drugs (NSAIDs)